American Society of Gene & Cell Therapy

09/08/2026

📢 We're less than one week away from the 2026 Policy Summit! Join us for a full day of high-impact discussions across regulatory, manufacturing, access, and innovation in CGT.

Can't make it in person? Attend virtually to get access to the same critical conversations from anywhere, plus the convenience of 30-day on-demand viewing after the event.

Register now ➡️ https://bit.ly/4wIMIem

09/04/2026

We’re grateful to Dr. Rami Major, PhD for her outstanding work as ASGCT’s 2025-2026 Congressional Policy Fellow. We are thankful for her advocacy and expertise to support evidence-based policymaking.

Dr. Major told us about her experience as our Congressional Policy Fellow:

"Though the problems that we are facing are large, my year in Congress taught me that there are plenty of capable and intelligent people behind the scenes working hard to find solutions. Science and scientific analysis play a crucial role in crafting effective policies, and it is up to all of us to make sure we are effectively communicating data that can drive policy. I will carry the lessons I've learned this past year with me throughout my professional career to become a better advocate for the science and innovation that we all benefit from." - Rami Major, PhD

09/02/2026

The September 2026 issue of Molecular Therapy is now live! Check it out here: https://bit.ly/4nz1L4T

09/01/2026

Gene therapy is not always the first step when it comes to one's treatment journey. Before some cell and gene therapies can be given, patients first undergo a step called conditioning.

Conditioning can help by:
✅ Creating space in the bone marrow for new or modified cells.
✅ Reducing the chance that the immune system interferes with the therapy.
✅ Improving the likelihood that the therapy will work as intended

While the modified cells often get the spotlight, conditioning is an important part of the treatment journey that helps set the stage for long-term success.

Check out the full unit on this topic at patienteducation.asgct.org.

08/31/2026

ASGCT is urging HHS OIG to establish clearer protections for clinical trial participant support, including a safe harbor for reasonable participation-related costs, reducing barriers to research while preserving patient safeguards.

Read more: https://bit.ly/4h2FTyU

The unbiased source for reliable, scientific information, news, and breakthroughs in gene and cell therapy.

08/28/2026

Can’t join us in person? Attend from anywhere!

The Policy Summit brings together leaders across policy, regulation, reimbursement, research, industry and patient advocacy for the conversations shaping the future of CGT.

Join virtually to hear directly from FDA experts, including Deputy Commissioner for Policy, Legislation, and International Affairs Grace Graham, MPP, on the Agency’s top CGT priorities and the future of regulation, plus insights from Andrew Byrnes, PhD and Kimberly Schultz, PhD.

Register for virtual access and tune into the conversation from wherever you are: https://bit.ly/4wIMIem

08/26/2026

Join leading minds in oncology for a two half-day virtual event exploring the latest advancements in cell and gene therapies for cancer.

Hear from pioneering researchers and innovators as they dive into some of the most compelling areas shaping CGTs for cancer today.

The presentations will cover:
• Precision gene engineering for programmable immune cell therapies
• The in vivo cell therapy frontier
• Novel approaches to CAR architecture
• Reprogramming the tumor microenvironment


Beyond the presentations, take the conversation further through interactive breakout sessions and live Q&As designed to encourage discussion, connection and deeper exploration of the field’s biggest opportunities and challenges.

Register today to be part of the conversation. https://bit.ly/4aX9OVW

08/26/2026

Join leading minds in oncology for a two half-day virtual event exploring the latest advancements in cell and gene therapies for cancer. 

Hear from pioneering researchers and innovators as they dive into some of the most compelling areas shaping CGTs for cancer today. Beyond the presentations, take the conversation further through interactive breakout sessions and live Q&As designed to encourage discussion, connection and deeper exploration of the field’s biggest opportunities and challenges.

08/26/2026

The FDA has approved Genglycos (pariglasgene brecaparvovec), an AAV gene therapy developed by Ultragenyx Pharmaceuticals, for treatment of Glycogen Storage Disease Type Ia (GSDIa) in patients 8 years of age and older with a documented history of hypoglycemia requiring intensive dietary management. This approval marks the first approved therapy of its kind for individuals born with GSDIa.

Read our full blog post about the approval here:

The unbiased source for reliable, scientific information, news, and breakthroughs in gene and cell therapy.

08/25/2026

There’s still time to share your research!

We've extended our abstract submission deadline to September 1.

Don’t miss the opportunity to contribute to the conversations shaping what’s next.

Register and submit your abstract here: https://bit.ly/4wHH10l